Related Experiment Video
Updated: Aug 9, 2025

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Targeting the gut-lung axis by synbiotic feeding to infants in a randomized controlled trial
Kotryna Simonyté Sjödin1, Andreas Sjödin1,2, Marek Ruszczyński3
1Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, 901 85, Sweden.
Insights
Synbiotics in infant formula promote beneficial gut bacteria like Bifidobacterium breve and reduce harmful Klebsiella, potentially preventing infections. This study highlights synbiotics
Area of Science:
- Microbiology
- Immunology
- Pediatrics
Background:
- Formula-fed infants face higher infection risks due to immature gut microbiota.
- The gut-lung axis suggests gut health can influence respiratory infections.
- Synbiotics (prebiotics and probiotics) may modulate infant gut microbiota and prevent infections.
Purpose of the Study:
- To investigate the impact of synbiotics on gut microbiota development in formula-fed infants.
- To compare the effects of prebiotic-only formula versus synbiotic formula.
- To analyze the relationship between gut microbiota composition and lower respiratory tract infections.
Main Methods:
- Randomized controlled trial of formula-fed infants from 1 to 6 months.
- Fecal sample analysis using 16S rRNA gene sequencing and multi-omics (GC-MS/LC-MS).
- Deep metagenomic sequencing for analyzing the fecal metagenome and antibiotic resistome in infection cases and controls.
Main Results:
- Synbiotic group showed lower Klebsiella and higher Bifidobacterium breve abundance compared to prebiotic-only group.
- Increased levels of the antimicrobial metabolite d-3-phenyllactic acid were observed in the synbiotic group.
- Infants with lower respiratory tract infections had higher Klebsiella abundance and related antimicrobial resistance genes.
Conclusions:
- Synbiotics offer additional benefits over prebiotics alone for formula-fed infants.
- Synbiotic feeding promotes beneficial bacteria and metabolites, impacting gut-lung and gut-skin axes.
- Synbiotic formula warrants clinical evaluation for infection prevention in infants unable to breastfeed.
Background:
Formula-fed infants are at increased risk of infections. Due to the cross-talk between the mucosal systems of the gastrointestinal and respiratory tracts, adding synbiotics (prebiotics and probiotics) to infant formula may prevent infections even at distant sites. Infants that were born full term and weaned from breast milk were randomized to prebiotic formula (fructo- and galactooligosaccharides) or the same prebiotic formula with Lactobacillus paracasei ssp. paracasei F19 (synbiotics) from 1 to 6 months of age. The objective was to examine the synbiotic effects on gut microbiota development.
Results:
Fecal samples collected at ages 1, 4, 6, and 12 months were analyzed using 16S rRNA gene sequencing and a combination of untargeted gas chromatography-mass spectrometry/liquid chromatography-mass spectrometry. These analyses revealed that the synbiotic group had a lower abundance of Klebsiella, a higher abundance of Bifidobacterium breve compared to the prebiotic group, and increases in the anti-microbial metabolite d-3-phenyllactic acid. We also analyzed the fecal metagenome and antibiotic resistome in the 11 infants that had been diagnosed with lower respiratory tract infection (cases) and 11 matched controls using deep metagenomic sequencing. Cases with lower respiratory tract infection had a higher abundance of Klebsiella species and antimicrobial resistance genes related to Klebsiella pneumoniae, compared to controls. The results obtained using 16S rRNA gene amplicon and metagenomic sequencing were confirmed in silico by successful recovery of the metagenome-assembled genomes of the bacteria of interest.
Conclusions:
This study demonstrates the additional benefit of feeding specific synbiotics to formula-fed infants over prebiotics only. Synbiotic feeding led to the underrepresentation of Klebsiella, enrichment of bifidobacteria, and increases in microbial degradation metabolites implicated in immune signaling and in the gut-lung and gut-skin axes. Our findings support future clinical evaluation of synbiotic formula in the prevention of infections and associated antibiotic treatment as a primary outcome when breastfeeding is not feasible.
Trial Registration:
ClinicalTrials.gov NCT01625273 . Retrospectively registered on 21 June 2012.
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Gastrointestinal Motility Disorders
Physiology of Enteric Nervous System and Gut Health

